Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection: An Analysis of the DARE-19 Randomized Controlled Trial. Issue 5 (May 2022)

• Record Type: Journal Article
• Authors: Heerspink, Hiddo J.L.; Furtado, Remo H.M.; Berwanger, Otavio; Koch, Gary G.; Martinez, Felipe; Mukhtar, Omar; Verma, Subodh; Gasparyan, Samvel B.; Tang, Fengming; Windsor, Sheryl L.; de Souza-Dantas, Vicente Cés; del Sueldo, Mildren; Frankel, Robert; Javaheri, Ali; Maldonado, Rafael A.; Morse, Caryn; Mota-Gomes, Marco; Shemin, Douglas; Silva, Osvaldo Lourenço; Tognon, Alexandre Pereira; Twahirwa, Marcel; Buenconsejo, Joan; Esterline, Russell; Oscarsson, Jan; Ambery, Philip; Langkilde, Anna Maria; Kosiborod, Mikhail N.
• Is Part Of: Clinical journal of the American Society of Nephrology. Volume 17:Issue 5(2022)
• Page Start: 643
• Page End: 654
• Publication Date: 2022-05
• Subjects: acute kidney injury -- chronic kidney disease -- COVID-19 -- diabetes -- heart failure -- hospitalization -- mortality risk -- outcomes -- randomized controlled trials -- cardiovascular disease
• DOI: 10.2215/CJN.14231021
• Languages: English
• ISSNs: 1555-9041

Abstract

Visual Abstract: Abstract : Background and objectives: Patients who were hospitalized with coronavirus disease 2019 (COVID-19) infection are at high risk of AKI and KRT, especially in the presence of CKD. The Dapagliflozin in Respiratory Failure in Patients with COVID-19 (DARE-19) trial showed that in patients hospitalized with COVID-19, treatment with dapagliflozin versus placebo resulted in numerically fewer participants who experienced organ failure or death, although these differences were not statistically significant. We performed a secondary analysis of the DARE-19 trial to determine the efficacy and safety of dapagliflozin on kidney outcomes in the overall population and in prespecified subgroups of participants defined by baseline eGFR. Design, setting, participants, & measurements: The DARE-19 trial randomized 1250 patients who were hospitalized (231 [18%] had eGFR <60 ml/min per 1.73 m 2 ) with COVID-19 and cardiometabolic risk factors to dapagliflozin or placebo. Dual primary outcomes (time to new or worsened organ dysfunction or death, and a hierarchical composite end point of recovery [change in clinical status by day 30]), and the key secondary kidney outcome (composite of AKI, KRT, or death), and safety were assessed in participants with baseline eGFR <60 and ≥60 ml/min per 1.73 m 2 . Results: The effect of dapagliflozin versus placebo on the primary prevention outcome (hazard ratio, 0.80; 95% confidence interval, 0.58 to 1.10), primary recovery outcome (win ratio, 1.09; 95% confidence interval, 0.97 to 1.22), and the composite kidney outcome (hazard ratio, 0.74; 95% confidence interval, 0.50 to 1.07) were consistent across eGFR subgroups ( P for interaction: 0.98, 0.67, and 0.44, respectively). The effects of dapagliflozin on AKI were also similar in participants with eGFR <60 ml/min per 1.73 m 2 (hazard ratio, 0.71; 95% confidence interval, 0.29 to 1.77) and ≥60 ml/min per 1.73 m 2 (hazard ratio, 0.69; 95% confidence interval, 0.37 to 1.29). Dapagliflozin was well tolerated in participants with eGFR <60 and ≥60 ml/min per 1.73 m 2 . Conclusions: The effects of dapagliflozin on primary and secondary outcomes in hospitalized participants with COVID-19 were consistent in those with eGFR below/above 60 ml/min per 1.73 m 2 . Dapagliflozin was well tolerated and did not increase the risk of AKI in participants with eGFR below or above 60 ml/min per 1.73 m 2 .